ALLMedicine Bacterial Vaginosis Center

May 21st, 2020 - To evaluate adherence and acceptability of intermittent vaginal probiotic or antibiotic use to prevent bacterial vaginosis (BV) recurrence. Repeated adherence and acceptability assessments using mixed methods within a pilot randomised controlled t...

May 13th, 2020 - Bacterial vaginosis affects 15 to 50% of women of reproductive age, and recurrence is common after treatment with an antibiotic agent. The high incidence of recurrence suggests the need for new treatments to prevent recurrent bacterial vaginosis. ...

May 12th, 2020 - Objective: To develop and characterize innovative vaginal dosage forms for the treatment of bacterial vaginosis (BV).Significance: This study is the first comparative evaluation of the metronidazole (MET)-loaded polyvinylpyrrolidone (PVP) nanofibe...

May 6th, 2020 - Bacterial vaginosis (BV) is a common cause of vaginal discharge and associated with vaginal acquisition of BV-associated bacteria (BVAB). We used quantitative PCR assays to determine if presence or concentrations of BVAB in the mouth, anus, vagina...

May 5th, 2020 - The aim of the study was to test the hypothesis that 5% monolaurin vaginal gel, a naturally occurring monoglyceride shown to have antimicrobial effects on vaginal pathogens without affecting Lactobacillus species, cures bacterial vaginosis (BV). T...

Apr 7th, 2020 - Bacterial vaginosis is common and is caused by a disruption of the microbiological environment in the lower genital tract. In the US, reported prevalence of bacterial vaginosis among pregnant women ranges from 5.8% to 19.3% and is higher in some r...

Oct 7th, 2019 - The USPSTF recommends against screening for bacterial vaginosis (BV) in pregnant persons who are not at increased risk for preterm delivery.

Jul 21st, 2017 - To review the evidence and provide recommendations on screening for and management of bacterial vaginosis in pregnancy. The clinical practice options considered in formulating the guideline. Outcomes evaluated include antibiotic treatment efficacy...

Jun 4th, 2015

May 23rd, 2015 - To review the evidence and provide recommendations on screening for and management of vulvovaginal candidiasis, trichomoniasis, and bacterial vaginosis. OUTCOMES evaluated include the efficacy of antibiotic treatment, cure rates for simple and com...

May 21st, 2020 - To evaluate adherence and acceptability of intermittent vaginal probiotic or antibiotic use to prevent bacterial vaginosis (BV) recurrence. Repeated adherence and acceptability assessments using mixed methods within a pilot randomised controlled t...

May 13th, 2020 - (Reuters Health) — Researchers say they have cut the recurrence rate of bacterial vaginosis by one third using an experimental treatment that injects a bacterium known as Lactin-V into the vagina to crowd out the noxious organisms that cause the c...

May 13th, 2020 - Bacterial vaginosis affects 15 to 50% of women of reproductive age, and recurrence is common after treatment with an antibiotic agent. The high incidence of recurrence suggests the need for new treatments to prevent recurrent bacterial vaginosis. ...

May 12th, 2020 - Objective: To develop and characterize innovative vaginal dosage forms for the treatment of bacterial vaginosis (BV).Significance: This study is the first comparative evaluation of the metronidazole (MET)-loaded polyvinylpyrrolidone (PVP) nanofibe...

May 6th, 2020 - Bacterial vaginosis (BV) is a common cause of vaginal discharge and associated with vaginal acquisition of BV-associated bacteria (BVAB). We used quantitative PCR assays to determine if presence or concentrations of BVAB in the mouth, anus, vagina...

May 13th, 2020 - (Reuters Health) — Researchers say they have cut the recurrence rate of bacterial vaginosis by one third using an experimental treatment that injects a bacterium known as Lactin-V into the vagina to crowd out the noxious organisms that cause the c...

Apr 8th, 2020 - NEW YORK (Reuters Health) - Based on updated evidence, the US Preventive Services Task Force (USPSTF) has reiterated its 2008 recommendation against screening for asymptomatic bacterial vaginosis in pregnant women who are not at increased risk for...

Mar 29th, 2020 - Safety and next steps The safety analysis showed that side effects were generally mild and well tolerated. There were 161 adverse events among 29 women for whom safety data were available.

Oct 8th, 2019 - Insufficient evidence exists to recommend routine screening for pregnant women at higher risk of preterm birth for bacterial vaginosis, the U.S. Preventive Services Task Force (USPSTF) said. There was not enough evidence to determine the benefits ...

Oct 7th, 2019 - The USPSTF recommends against screening for bacterial vaginosis (BV) in pregnant persons who are not at increased risk for preterm delivery.